Comparative Pharmacology
Head-to-head clinical analysis: FURALAN versus MACROBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FURALAN versus MACROBID.
FURALAN vs MACROBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Nitrofurantoin is a urinary tract antibacterial agent that inhibits bacterial acetyl-CoA carboxylase, disrupting cell wall synthesis and bacterial respiration. It is reduced by bacterial nitroreductases to reactive intermediates that damage DNA, ribosomes, and other macromolecules.
20 mg orally three times daily for 7 days.
100 mg orally twice daily with food for 7 days.
None Documented
None Documented
Terminal elimination half-life is 8–12 hours in adults with normal renal function; this supports twice-daily dosing. In patients with creatinine clearance <30 mL/min, half-life may be prolonged to 20–30 hours, requiring dose adjustment.
Terminal elimination half-life: 0.3-1.0 hour (short) due to rapid renal clearance and tissue metabolism; no accumulation with twice-daily dosing. The short half-life is adequate for urinary tract exposure.
Approximately 65–70% of an administered dose is excreted unchanged via renal glomerular filtration and tubular secretion; about 10–15% appears in bile as parent drug or glucuronide conjugate; up to 20% is eliminated in feces via unabsorbed fraction or biliary elimination.
Renal: 36% (unchanged nitrofurantoin) and 15% (metabolites) within 24 hours. Total renal elimination: 51%. Biliary/fecal: 1-2%. Additional 30% undergoes rapid metabolic degradation in tissues.
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective